Preclinical studies suggest that ADCs linked to microtubule-depolymerizing agents can induce immunogenic cell death and enhance anti-tumor immune activity, by stimulating the population of intratumoral CD45+ dendritic cells [51,52]. The gene discussed is PTPRC; the disease is neoplasm.